Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice

Susanne Neschen, Markus Scheerer, Anett Seelig, Peter Huypens, Jürgen Schultheiss, Moya Wu, Wolfgang Wurst, Birgit Rathkolb, Karsten Suhre, Eckhard Wolf, Johannes Beckers, Martin Hrabé De Angelis

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Combined use of metformin and a sodium glucose cotransporter 2 inhibitor (SGLT2I) is a promising treatment strategy for type 2 diabetes. The mechanism by which combination treatment provides better glycemic control than metformin or SGLT2I monotherapy remains elusive. Therefore, we investigated the physiological mechanism by which both compounds lower blood glucose concentrations in diabetic mice. We compared the potential of metformin and the SGLT2I AVE2268 alone or in combination to mitigate hyperglycemia andmodulate glucose fluxes in db/db and diabetic Tallyho/JngJ mice. SGLT2I treatment alone elicited a rapid decline in circulating blood glucose levels, which appeared to induce endogenous glucose production. Supplementation of metformin dampened this counterresponse, and therefore, combination therapy more efficiently maintained glycemic control. Finally, combination treatment blunted postprandial glucose excursions and improved HbA1c levels within 2 weeks. We conclude that coapplication of metformin enhances the glucoselowering actions of SGLT2I by restraining endogenous glucose production, which may provide long-term improvement of glycemic control in type 2 diabetic patients.

Original languageEnglish
Pages (from-to)284-290
Number of pages7
JournalDiabetes
Volume64
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Fingerprint

Sodium-Glucose Transport Proteins
Metformin
Hypoglycemic Agents
Glucose
Blood Glucose
Therapeutics
Hyperglycemia
Type 2 Diabetes Mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice. / Neschen, Susanne; Scheerer, Markus; Seelig, Anett; Huypens, Peter; Schultheiss, Jürgen; Wu, Moya; Wurst, Wolfgang; Rathkolb, Birgit; Suhre, Karsten; Wolf, Eckhard; Beckers, Johannes; De Angelis, Martin Hrabé.

In: Diabetes, Vol. 64, No. 1, 01.01.2015, p. 284-290.

Research output: Contribution to journalArticle

Neschen, S, Scheerer, M, Seelig, A, Huypens, P, Schultheiss, J, Wu, M, Wurst, W, Rathkolb, B, Suhre, K, Wolf, E, Beckers, J & De Angelis, MH 2015, 'Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice', Diabetes, vol. 64, no. 1, pp. 284-290. https://doi.org/10.2337/db14-0393
Neschen, Susanne ; Scheerer, Markus ; Seelig, Anett ; Huypens, Peter ; Schultheiss, Jürgen ; Wu, Moya ; Wurst, Wolfgang ; Rathkolb, Birgit ; Suhre, Karsten ; Wolf, Eckhard ; Beckers, Johannes ; De Angelis, Martin Hrabé. / Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice. In: Diabetes. 2015 ; Vol. 64, No. 1. pp. 284-290.
@article{1c5f156366584c4995a70783f160812e,
title = "Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice",
abstract = "Combined use of metformin and a sodium glucose cotransporter 2 inhibitor (SGLT2I) is a promising treatment strategy for type 2 diabetes. The mechanism by which combination treatment provides better glycemic control than metformin or SGLT2I monotherapy remains elusive. Therefore, we investigated the physiological mechanism by which both compounds lower blood glucose concentrations in diabetic mice. We compared the potential of metformin and the SGLT2I AVE2268 alone or in combination to mitigate hyperglycemia andmodulate glucose fluxes in db/db and diabetic Tallyho/JngJ mice. SGLT2I treatment alone elicited a rapid decline in circulating blood glucose levels, which appeared to induce endogenous glucose production. Supplementation of metformin dampened this counterresponse, and therefore, combination therapy more efficiently maintained glycemic control. Finally, combination treatment blunted postprandial glucose excursions and improved HbA1c levels within 2 weeks. We conclude that coapplication of metformin enhances the glucoselowering actions of SGLT2I by restraining endogenous glucose production, which may provide long-term improvement of glycemic control in type 2 diabetic patients.",
author = "Susanne Neschen and Markus Scheerer and Anett Seelig and Peter Huypens and J{\"u}rgen Schultheiss and Moya Wu and Wolfgang Wurst and Birgit Rathkolb and Karsten Suhre and Eckhard Wolf and Johannes Beckers and {De Angelis}, {Martin Hrab{\'e}}",
year = "2015",
month = "1",
day = "1",
doi = "10.2337/db14-0393",
language = "English",
volume = "64",
pages = "284--290",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "1",

}

TY - JOUR

T1 - Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice

AU - Neschen, Susanne

AU - Scheerer, Markus

AU - Seelig, Anett

AU - Huypens, Peter

AU - Schultheiss, Jürgen

AU - Wu, Moya

AU - Wurst, Wolfgang

AU - Rathkolb, Birgit

AU - Suhre, Karsten

AU - Wolf, Eckhard

AU - Beckers, Johannes

AU - De Angelis, Martin Hrabé

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Combined use of metformin and a sodium glucose cotransporter 2 inhibitor (SGLT2I) is a promising treatment strategy for type 2 diabetes. The mechanism by which combination treatment provides better glycemic control than metformin or SGLT2I monotherapy remains elusive. Therefore, we investigated the physiological mechanism by which both compounds lower blood glucose concentrations in diabetic mice. We compared the potential of metformin and the SGLT2I AVE2268 alone or in combination to mitigate hyperglycemia andmodulate glucose fluxes in db/db and diabetic Tallyho/JngJ mice. SGLT2I treatment alone elicited a rapid decline in circulating blood glucose levels, which appeared to induce endogenous glucose production. Supplementation of metformin dampened this counterresponse, and therefore, combination therapy more efficiently maintained glycemic control. Finally, combination treatment blunted postprandial glucose excursions and improved HbA1c levels within 2 weeks. We conclude that coapplication of metformin enhances the glucoselowering actions of SGLT2I by restraining endogenous glucose production, which may provide long-term improvement of glycemic control in type 2 diabetic patients.

AB - Combined use of metformin and a sodium glucose cotransporter 2 inhibitor (SGLT2I) is a promising treatment strategy for type 2 diabetes. The mechanism by which combination treatment provides better glycemic control than metformin or SGLT2I monotherapy remains elusive. Therefore, we investigated the physiological mechanism by which both compounds lower blood glucose concentrations in diabetic mice. We compared the potential of metformin and the SGLT2I AVE2268 alone or in combination to mitigate hyperglycemia andmodulate glucose fluxes in db/db and diabetic Tallyho/JngJ mice. SGLT2I treatment alone elicited a rapid decline in circulating blood glucose levels, which appeared to induce endogenous glucose production. Supplementation of metformin dampened this counterresponse, and therefore, combination therapy more efficiently maintained glycemic control. Finally, combination treatment blunted postprandial glucose excursions and improved HbA1c levels within 2 weeks. We conclude that coapplication of metformin enhances the glucoselowering actions of SGLT2I by restraining endogenous glucose production, which may provide long-term improvement of glycemic control in type 2 diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=84919958374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919958374&partnerID=8YFLogxK

U2 - 10.2337/db14-0393

DO - 10.2337/db14-0393

M3 - Article

C2 - 25071027

AN - SCOPUS:84919958374

VL - 64

SP - 284

EP - 290

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 1

ER -